UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 12, 2023

 

BIONEXUS GENE LAB CORP.

(Exact name of Company as specified in charter) 

 

Wyoming

333-229399

35-2604830

(State or another jurisdiction

of incorporation)

(Commission

File No.)

(IRS Employer

Identification No.)

 

Unit 2, Level 10, Tower B, Avenue 3

The Vertical Business Suite II Bangar South

No. 8 Jalan Kerinchi

Kuala Lumpur, Malaysia, 59200

(Address of Principal Executive Offices) (Zip code)

 

+60 1221-26512

(Company’s Telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, no par value

 

BGLC

 

Nasdaq Capital Market

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Chi Yuen Leong as Chief Executive Officer and Director.

 

On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. (“the Company”) approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023.

 

Mr. Leong has no family relationship with any director or executive officer of the Company. He was not involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

 

Mr. Leong, aged 72, has extensive experience in management, commercialization, finance, and the biotechnology industry. He served as the President and director from the Company’s inception to August 2022 and has been working with and guiding the Company’s successful listing on OTC and Nasdaq. He joined the US Arem Pacific Corporation as the Chief Executive Officer from March 1, 2009, until September 30, 2015. Mr. Leong received a Bachelor of Behavioral Sciences from the University of East Asia, Malaysia. Mr. Leong brings a wide range of business experience, including experience with public companies, to our board of directors.  

 

Mr. Leong entered into an employment agreement with the Company dated October 12, 2023, and agreed to receive an annual compensation of $24,000.

 

 

2

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BIONEXUS GENE LAB CORP

 

 

 

 

Date: October 16, 2023

By:

/s/ Chi Yuen Leong

 

 

Name:

Chi Yuen Leong

 

 

Title:

Chief Executive Officer

 

 

 

3

  

v3.23.3
Cover
Oct. 12, 2023
Cover [Abstract]  
Entity Registrant Name BIONEXUS GENE LAB CORP.
Entity Central Index Key 0001737523
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Oct. 12, 2023
Entity Ex Transition Period false
Entity File Number 333-229399
Entity Incorporation State Country Code WY
Entity Tax Identification Number 35-2604830
Entity Address Address Line 1 Unit 2, Level 10, Tower B, Avenue 3
Entity Address Address Line 2 The Vertical Business Suite II Bangar South
Entity Address Address Line 3 No. 8 Jalan Kerinchi
Entity Address City Or Town Kuala Lumpur
Entity Address Country MY
Entity Address Postal Zip Code 59200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Local Phone Number 1221-26512
Security 12b Title Common Stock, no par value
Trading Symbol BGLC
Security Exchange Name NASDAQ
City Area Code 60
BioNexus Gene Lab (PK) (USOTC:BGLC)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more BioNexus Gene Lab (PK) Charts.
BioNexus Gene Lab (PK) (USOTC:BGLC)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more BioNexus Gene Lab (PK) Charts.